Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...
AMG-193 by Amgen for Metastatic Biliary Tract Cancer: Likelihood of Approval
AMG-193 is under clinical development by Amgen and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...
Bemarituzumab by Amgen for Lung Adenocarcinoma: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
Carfilzomib by Amgen for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Carfilzomib is under clinical development by Amgen and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Denosumab by Amgen for Male Infertility: Likelihood of Approval
Denosumab is under clinical development by Amgen and currently in Phase II for Male Infertility. According to GlobalData, Phase II...
Bemarituzumab by Amgen for Peritoneal Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...
Blinatumomab by Amgen for Lymphoblastic Lymphoma: Likelihood of Approval
Blinatumomab is under clinical development by Amgen and currently in Phase III for Lymphoblastic Lymphoma. According to GlobalData, Phase III...
Sotorasib by Amgen for Colorectal Cancer: Likelihood of Approval
Sotorasib is under clinical development by Amgen and currently in Pre-Registration for Colorectal Cancer. According to GlobalData, Pre-Registration drugs for...
Bemarituzumab by Amgen for Fallopian Tube Cancer: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...
Talimogene laherparepvec by Amgen for Metastatic Renal Cell Carcinoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Renal Cell Carcinoma. According to...
Talimogene laherparepvec by Amgen for Metastatic Colorectal Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData,...
Talimogene laherparepvec by Amgen for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Talimogene laherparepvec by Amgen for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC). According to...
Talimogene laherparepvec by Amgen for Non-Small Cell Lung Cancer: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Non-Small Cell Lung Cancer. According to...
Talimogene laherparepvec by Amgen for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
Talimogene laherparepvec by Amgen for Kaposi Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Kaposi Sarcoma. According to GlobalData, Phase...
Bemarituzumab by Amgen for Lung Adenocarcinoma: Likelihood of Approval
Bemarituzumab is under clinical development by Amgen and currently in Phase II for Lung Adenocarcinoma. According to GlobalData, Phase II...
Carfilzomib by Amgen for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Carfilzomib is under clinical development by Amgen and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Erenumab by Amgen for Pain: Likelihood of Approval
Erenumab is under clinical development by Amgen and currently in Phase II for Pain. According to GlobalData, Phase II drugs...
Rozibafusp alfa by Amgen for Systemic Lupus Erythematosus: Likelihood of Approval
Rozibafusp alfa is under clinical development by Amgen and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData,...